NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 8.80 against a street estimate of 7.79 — a beat of 13.0%.
with an average price target of ₹952.80.
CONFIDENT APLLTD delivered 26% YoY revenue growth in Q1 FY'27 on broad-based momentum: U.S. Generics +49%, India Branded +7%, API +33%. Raised FY'27 guidance to mid-teens from low double-digits. Core EBITDA margin expanding; U.S. branded business launch absorbing 150bps dilution but expected positive contribution next year. Q1 FY'27 (ended 30 June 2026) U.S. Generics driving consolidated momentum. Constant currency U.S. growth ~37–38% after ~10% INR depreciation benefit. India underperforming relative to market; management initiating leadership changes to improve execution. Analysts pressed on Bosutinib sustainability (small volume, high price; uncertain post-November), U.S. branded timeline to profitability (next FY expected), India execution turnaround (2-quarter visibility), and margin trajectory (operating leverage confirmed but offset by branded dilution). Management candid on low-p…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call ALEMBIC PHARMACEUTICALS LIMITED - Q1 FY27 SUMMARY HEADLINE NUMBERS • Consolidated revenue grew 26% year-on-year to INR 2,150 crores • EBITDA grew 21 | 2026-08-10 |
| Quarterly results · Q1 FY27 ALEMBIC PHARMACEUTICALS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Revenue from operations: Rs. 2,150 Cr in Q1 FY27, up 26% YoY (Q1 FY26: Rs. 1,71 | 2026-08-04 |
| Investor presentation · Q1 FY27 ALEMBIC PHARMACEUTICALS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Total Revenue: INR 21.50 billion (+26% YoY, +16% QoQ) • EBITDA before R&D: INR | 2026-08-04 |
| Annual report FY2026 ALEMBIC PHARMACEUTICALS LIMITED – ANNUAL REPORT FY26 SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹7,345 crore, up 10% YoY • EBITDA: ₹1,177 c | 2026-07-10 |
| Q4 FY26 earnings call ALEMBIC PHARMACEUTICALS LIMITED – Q4 FY '26 SUMMARY HEADLINE NUMBERS • Q4 FY '26 Revenue: INR 1,838 crores, up 4% year-on-year • Full Year FY '26 Re | 2026-05-21 |
| Quarterly results · Q4 FY26 ALEMBIC PHARMACEUTICALS LIMITED – FINANCIAL SUMMARY HEADLINE NUMBERS • FY 2025-26 Revenue from Operations: Rs 6,651.38 crore (standalone), Rs 7,344. | 2026-05-15 |
| Investor presentation · Q4 FY26 ALEMBIC PHARMACEUTICALS LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Total Revenue FY26: INR 73.45 billion (+10% YoY); Q4 FY26: INR 18.48 billion (+ | 2026-05-15 |
| Q3 FY26 earnings call ALEMBIC PHARMACEUTICALS LIMITED – Q3 FY '26 SUMMARY HEADLINE NUMBERS • Q3 Revenue: INR 1,876 crores, up 11% year-over-year • 9-Month Revenue: INR 5, | 2026-02-11 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹12 / share ex-date Jul 29, 2026 | 2026-07-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alembic Pharmaceuticals Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.